How long did you take this medication to work?
Dosage of Moxijet in details
Dosage in Adult Patients
The dose of Moxijet is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection as described in Table 1.
Type of Infectiona
Every 24 hours
Community Acquired Pneumonia (1.1)
Uncomplicated Skin and Skin Structure Infections (SSSI ) (1.2)
Complicated SSSI (1.3)
Complicated Intra-Abdominal Infections (1.4)
Acute Bacterial Sinusitis (ABS) (1.6)
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) (1.7)
- Due to the designated pathogens.
- Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician
- Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis.
Oral Dosing in Adults
Intravenous formulation is indicated when it offers a route of administration advantageous to the patient (for example, patient cannot tolerate an oral dosage form). When switching from intravenous to oral formulation, no dosage adjustment is necessary. Patients whose therapy is started with Moxijet Injection may be switched to Moxijet Tablets when clinically indicated at the discretion of the physician.
Important Administration Instructions
With Multivalent Cations
Administer Moxijet Tablets at least 4 hours before or 8 hours after products containing magnesium, aluminum, iron or zinc, including antacids, sucralfate, multivitamins and didanosine buffered tablets for oral suspension or the pediatric powder for oral solution.
Moxijet Tablets can be taken with or without food, drink fluids liberally.
Intravenous infusion only. It is not intended for intra-arterial, intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.
Administer by intravenous infusion over a period of 60 minutes by direct infusion or through a Y-type intravenous infusion set which may already be in place. Avoid rapid or bolus intravenous infusion.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Discard any unused portion because the premix flexible containers are for single-use only.
Drug and Diluent Compatibilities
Because only limited data are available on the compatibility of Moxijet intravenous injection with other intravenous substances, additives or other medications should not be added to Moxijet Injection or infused simultaneously through the same intravenous line. If the same intravenous line or a Y-type line is used for sequential infusion of other drugs, or if the “piggyback” method of administration is used, the line should be flushed before and after infusion of Moxijet Injection with an infusion solution compatible with Moxijet Injection as well as with other drug(s) administered via this common line.
Intravenous Solutions: Moxijet Injection is compatible with the following intravenous solutions at ratios from 1:10 to 10:1:
0.9% Sodium Chloride Injection, USP
1 Molar Sodium Chloride Injection
5% Dextrose Injection, USP
Sterile Water for Injection, USP
10% Dextrose for Injection, USP
Lactated Ringer’s for Injection
Preparation for Administration of Moxijet Injection
Refer to complete directions that have been provided with the administration set.
To prepare Moxijet Injection premix in flexible containers:
- Close flow control clamp of administration set.
- Remove cover from port at bottom of container.
- Insert piercing pin from an appropriate transfer set (for example, one that does not require excessive force, such as ISO compatible administration set) into port with a gentle twisting motion until pin is firmly seated.
What other drugs will affect Moxijet?
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Moxijet, especially:
a diuretic or "water pill";
insulin or oral diabetes medicine;
a blood thinner--warfarin, Coumadin, Jantoven;
heart rhythm medication--amiodarone, disopyramide, dofetilide, dronedarone, procainamide, quinidine, sotalol, and others;
medicine to treat depression or mental illness--amitriptylline, clomipramine, desipramine, iloperidone, imipramine, nortriptyline, and others;
NSAIDs (nonsteroidal anti-inflammatory drugs)--aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, indomethacin, meloxicam, and others; or
steroid medicine--prednisone, dexamethasone, methylprednisolone, and others.
This list is not complete. Other drugs may interact with Moxijet, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Tablet: For the following substances, absence of a clinically relevant interaction with Moxijet was proven: Atenolol, ranitidine, calcium supplements, theophylline, oral contraceptives, glibenclamide, itraconazole, digoxin, morphine, probenecid. No dose adjustment is necessary for these drugs.
Antacids, Minerals and Multivitamins: Concomitant ingestion of Moxijet with antacids, minerals and multivitamins may result in impaired absorption of Moxijet after oral administration due to formation of chelate complexes with the multivalent cations contained in these preparations. This may lead to plasma concentrations considerably lower than desired. Hence, antacids, antiretroviral drugs (eg, didanosine) and other preparations containing magnesium or aluminium, sucralfate and agents containing iron or zinc should be administered at least 4 hours before or 2 hours after ingestion of an oral Moxijet dose.
Ranitidine: The concomitant administration with ranitidine did not change the absorption characteristics of Moxijet. Absorption parameters (Cmax, tmax, AUC) were comparable, indicating absence of an influence of gastric pH on Moxijet uptake from the gastrointestinal tract.
Calcium Supplements: When given with high dose calcium supplements, only a slightly reduced rate of absorption was observed, while extent of absorption remained unaffected. The effect of high-dose calcium supplements on the absorption of Moxijet is considered as clinically not relevant.
Theophylline: In accordance with in vitro data, no influence of Moxijet on theophylline pharmacokinetics (and vice versa) at steady state was detected in humans, indicating that Moxijet does not interfere with the 1A2 subtypes of the CYP450 enzymes.
Warfarin: No interaction during concomitant treatment with warfarin on pharmacokinetics, prothrombin time and other coagulation parameters has been observed.
Changes in International Normalized Ratio (INR): Cases of increased anticoagulant activity have been reported in patients receiving anticoagulants concurrently with antibiotics, including Moxijet. The infectious disease (and its accompanying inflammatory process), age and general status of the patient are risk factors. Although an interaction between Moxijet and warfarin was not demonstrated in clinical trials, INR monitoring should be performed and, if necessary, the oral anticoagulant dosage should be adjusted as appropriate.
Oral Contraceptives:No interaction has occured following concomitant oral administration of Moxijet with oral contraceptives.
Antidiabetics: No clinically relevant interaction was seen between glibenclamide and Moxijet.
Itraconazole: Exposure (AUC) to itraconazole was only marginally altered under concomitant Moxijet treatment. Pharmacokinetics of Moxijet were not significantly altered by itraconazole. No dose adjustment is necessary for itraconazole when given with Moxijet and vice versa.
Digoxin: The pharmacokinetics of digoxin are not significantly influenced by Moxijet (and vice versa). After repeated dosing in healthy volunteers, Moxijet increased Cmax of digoxin by approximately 30% at steady state without affecting AUC or trough levels.
Parenteral administration of morphine with Moxijet did not reduce the oral bioavailability of Moxijet and only slighlty decreased Cmax (17 %).
Atenolol: The pharmacokinetics of atenolol are not significantly altered by Moxijet. Following single dose administration in healthy subjects, AUC was marginally increased (by approximately 4%) and peak concentrations were decreased by 10%.
Probenecid: No significant effect on apparent total body clearance and renal clearance of Moxijet was found in a clinical study investigating the impact of probenecid on renal excretion.
Charcoal: Concomitant dosing of charcoal and oral Moxijet 400 mg reduced the systemic availability of the drug by >80% by preventing absorption in vivo. The application of activated charcoal in the early absorption phase prevents further increase of systemic exposure in cases of overdose.
After IV drug administration, carbo medicinalis only slightly reduces systemic exposure (approximately 20%).
Food and Dairy Products: Absorption of Moxijet was not altered by food intake (including dairy products). Moxijet can be taken independent from food intake.
Infusion: No interaction during concomitant treatment with warfarin, itraconazole, theophylline, digoxin and oral contraceptives.
- FDA/SPL Indexing Data. "U188XYD42P: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Moxijet are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Moxijet. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported frequency of useNo survey data has been collected yet
Consumer reported dosesNo survey data has been collected yet
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology